SAT-442 Crinecerfont Enables Reduction of Glucocorticoid Doses While Maintaining or Improving Androstenedione in Pediatric Patients with Classic Congenital Adrenal Hyperplasia: Subgroup Analyses From the Phase 3 CAHtalyst™ Pediatric Study.

Oksana Lekarev, Ayca Erkin-Cakmak, Maria G Vogiatzi, Erik A Imel, Maria Clemente, Regis Coutant, Gelliza B G Rosales, Eiry Roberts, George S Jeha, Robert H Farber, Jean L Chan. SAT-442 Crinecerfont Enables Reduction of Glucocorticoid Doses While Maintaining or Improving Androstenedione in Pediatric Patients with Classic Congenital Adrenal Hyperplasia: Subgroup Analyses From the Phase 3 CAHtalyst™ Pediatric Study. Journal of the Endocrine Society. 2025 Oct 22; 9(Supplement_1):bvaf149.310.